Maxim Group Cuts Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) Price Target to $3.00

Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) had its target price decreased by Maxim Group from $5.00 to $3.00 in a research note released on Friday morning,Benzinga reports. Maxim Group currently has a buy rating on the stock.

Several other equities research analysts also recently issued reports on the company. HC Wainwright raised their price target on Lineage Cell Therapeutics from $7.00 to $9.00 and gave the company a “buy” rating in a report on Wednesday, December 4th. D. Boral Capital reaffirmed a “buy” rating and set a $2.00 target price on shares of Lineage Cell Therapeutics in a report on Friday, January 3rd. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the company has a consensus rating of “Buy” and an average price target of $4.80.

Lineage Cell Therapeutics Stock Performance

NYSEAMERICAN LCTX opened at $0.58 on Friday. The firm has a market cap of $127.84 million, a price-to-earnings ratio of -4.83 and a beta of 1.16. Lineage Cell Therapeutics has a 1 year low of $0.48 and a 1 year high of $1.61.

Institutional Investors Weigh In On Lineage Cell Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the stock. SG Americas Securities LLC acquired a new position in shares of Lineage Cell Therapeutics during the 3rd quarter valued at $46,000. XTX Topco Ltd bought a new stake in Lineage Cell Therapeutics in the second quarter valued at $61,000. GSA Capital Partners LLP acquired a new position in shares of Lineage Cell Therapeutics during the third quarter valued at about $84,000. Rhumbline Advisers raised its holdings in shares of Lineage Cell Therapeutics by 15.1% during the second quarter. Rhumbline Advisers now owns 132,491 shares of the company’s stock valued at $132,000 after purchasing an additional 17,411 shares during the period. Finally, Barclays PLC grew its stake in shares of Lineage Cell Therapeutics by 311.3% in the 3rd quarter. Barclays PLC now owns 211,300 shares of the company’s stock valued at $192,000 after buying an additional 159,924 shares during the period. Institutional investors and hedge funds own 62.47% of the company’s stock.

Lineage Cell Therapeutics Company Profile

Lineage Cell Therapeutics, Inc, a clinical-stage biotechnology company, develops novel cell therapies for unmet medical needs in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer.